WeVote
Log In

Bill

Bill

A 1017

Relates to education and outreach for drug-induced movement disorders by the department of health

2025 Regular Session Introduced by Amy Paulin

Bill A 1017 boosts awareness of drug-induced movement disorders through education for healthcare providers and the public, improving diagnosis and care for affected individuals.

SIGNED CHAP.37
0
WeVote Research Nonpartisan
Bill Summary · A 1017

Summary of Bill A 1017

Bill Information

  • Bill Number: A 1017
  • Title: Relates to education and outreach for drug-induced movement disorders by the Department of Health
  • Status: Signed into law (Chapter 37)
  • Introduced: January 8, 2025
  • Classification: Legislative Bill

Purpose and Intent

Bill A 1017 aims to enhance public awareness and understanding of drug-induced movement disorders. These disorders can arise as side effects of certain medications, and the bill seeks to ensure that both healthcare providers and the general public are better informed about these conditions. The intent is to improve diagnosis, treatment, and management of these disorders through targeted education and outreach initiatives.

Key Provisions

  • Education Programs: The Department of Health is mandated to develop and implement educational programs focused on drug-induced movement disorders. These programs will target healthcare professionals, patients, and the general public.
  • Outreach Initiatives: The bill emphasizes outreach efforts to raise awareness about the symptoms, causes, and treatment options for drug-induced movement disorders.
  • Resource Development: The Department of Health will create and distribute informational materials, including brochures and online resources, to facilitate understanding and awareness of these disorders.

Affected Parties

  • Healthcare Providers: Physicians, pharmacists, and other healthcare professionals will benefit from enhanced training and resources, enabling them to better recognize and manage drug-induced movement disorders in their patients.
  • Patients and Caregivers: Individuals taking medications that may cause movement disorders, as well as their caregivers, will receive valuable information to help them identify symptoms and seek appropriate care.
  • General Public: The outreach initiatives will inform the broader community about the risks associated with certain medications and the importance of reporting any adverse effects.

Legislative Timeline

  • January 8, 2025: Bill A 1017 is introduced and referred to the Health Committee.
  • January 14, 2025: The bill is reported and ordered to a third reading.
  • January 22, 2025: The Assembly passes the bill and it is delivered to the Senate.
  • February 10, 2025: The Senate passes the bill, which is then returned to the Assembly.
  • February 12, 2025: The bill is delivered to the Governor.
  • February 14, 2025: The bill is signed into law, becoming Chapter 37.

Related Legislation

  • S 786: This bill serves as a companion to A 1017, likely addressing similar issues related to drug-induced movement disorders.

Conclusion

Bill A 1017 represents a significant step towards improving awareness and education surrounding drug-induced movement disorders. By equipping healthcare providers and the public with essential knowledge, the bill aims to enhance the quality of care for affected individuals and promote better health outcomes.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.